# FDA Approves Alembic's Generic Drug Application Alembic has received FDA approval for generic drug application ANDA216370, expanding the company's portfolio in the competitive generic pharmaceutical market and positioning it to capture market share as branded competitors face potential patent expirations. The approval strengthens Alembic's presence in the U.S. market and is expected to contribute to revenue growth through increased generic drug penetration in 2026 and beyond.